Why Akebia Shares Are Hitting New Highs
Akebia Therapeutics saw its shares hit a new 52-week high in Tuesday’s session following a key licensing agreement with Vifor Pharma.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 169
Did Pantheon Get Enough in Its Buyout?
Pantheon shares saw a huge gain on Monday following the announcement that the company will be acquired by Thermo Fisher Scientific.
Top Credit Suisse Pharma Picks Ahead of Catalysts
Credit Suisse provided its outlook for several large-cap pharmaceutical stocks Monday morning. The analyst has three top picks to consider.
Why Ionis Pharma Is Sinking Despite Solid Late-Stage Results
Ionis Pharmaceuticals saw its shares pullback on Monday morning after results were released from its late-stage trial for the treatment of familial amyloid polyneuropathy.
How Ebola Stocks Are Responding After the Outbreak in the Congo
The WHO has confirmed a new outbreak of the Ebola virus in the Democratic Republic of Congo. A few of the Ebola-related stocks are responding.
Ziopharm Prices Secondary Offering
Ziopharm Oncology saw its shares slide early on Friday after the company announced the pricing of its secondary offering.
G1 Therapeutics Announces Potential Pricing for IPO
G1 Therapeutics expects to offer more than 6 million shares in the range of $15 to $17 apiece in an initial public offering valued up to around $122 million.
Why Big Pharma Is Not at Fault for Record Drug Spending
With prescription drug spending breaking new records almost every year now, people like to blame Big Pharma and use it as the industry punching bag.
Merck’s Accelerated Keytruda Lung Cancer Approval Creates 3 Moves
It is no secret that pharma and biotech shares have had to deal with at least some headwinds over the past year. It turns out that drug pricing concerns and political oversight can still…
Why Sangamo Therapeutics Is Surging
Sangamo Therapeutics saw its shares skyrocket early on Thursday after a critical business update.
Major Biotech Short Interest Remains Mixed
The April 28 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
Short Interest in Major Pharma Shrinks
The April 28 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly downward.
4 Biotech and Specialty Pharma Stocks With 80% to 200% Upside Potential
The analysts at Stifel have focused on biotech and specialty pharma companies that not only have data that could prove to be huge, but they are offering aggressive accounts the best entry points in…
Is Valeant for Real This Time?
With earnings this positive and shares responding as a result, investors have to wonder if Valeant Pharmaceuticals is for real this time, or is this just a head fake.
How Valeant Earnings Beat Estimates
Canadian pharmaceutical maker Valeant posted a big beat on both earnings and revenues Tuesday morning. The company also raised its adjusted EBITDA guidance for the full fiscal year.